cholinergic urticaria
Conditions
Interventions
Conventional therapy:Oral standard therapeutic dose of second-generation antihistamines (ebastine hydrochloride or levocetirizine tablets)
Conventional therapy+NB-UVB:Oral standard therapeutic dose of second-generation antihistamines (ebastine hydrochloride or levocetirizine tablets)+NB-UVB treatment three times a week
Sponsors
Southwest hospital, Army Medical University, PLA
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1.Age: 18-60 years old; 2.The diagnosis was in accordance with the diagnostic criteria of cholinergic urticaria in the 2018 EAACI/GA2LEN/EDF/WAO guideline of urticaria, the Severity of symptoms was moderate to severe: urticaria control score (UCT) 10; 3.The patients had good compliance with the planned treatment, understood the research process of this study and signed written informed consent; 4.Volunteer to participate in this study and be willing to randomly receive one of the two treatment modalities.
Exclusion criteria
Exclusion criteria: 1.Accompanied by other types of chronic urticaria; 2.Patients with severe infections, malignant tumors, lupus erythematosus, dermatomyositis, xeroderma pigmentosus, porphyria, photosensitive skin diseases (such as pleomorphic solar rash, chronic photochemical dermatitis, solar urticaria, etc.), cataract and other diseases; Patients with a history of skin melanoma and non-melanoma; 3.Patients with diabetes mellitus, severe cardiac insufficiency, severe hepatic and renal insufficiency or other serious diseases; 4.Those who have used systemic immunosuppressants, glucocorticoids, biological agents, antibiotics, tretinoin, hydroxychloroquine sulfate, and antifungal drugs within the past 1 month; 5.Patients with a history of photochemotherapy within the past 1 month; 6. Pregnant and lactating women and patients of childbearing age who refused to take appropriate contraceptive measures during the trial; 7.Alcoholics, drug addicts and abnormal spirits; 8. Patients judged by the investigator to be unsuitable for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CholU Severity Index (CholU SI);Urticaria control test;autologous serum skin test (ASST); | — |
Secondary
| Measure | Time frame |
|---|---|
| Dermatology Quality of Life Score (DLQI) ; | — |
Countries
China
Contacts
Public ContactQiquan Chen
Southwest hospital, Army Medical University, PLA
Outcome results
None listed